Apparatus to administer the BCG vaccine in Japan (representational image) | Photo: ThePrint Team | Commons
Apparatus to administer the BCG vaccine in Japan (representational image) | Photo: ThePrint Team | Commons
Text Size:

Tokyo: The lead researcher on a trial of the Japanese antiviral Avigan to treat Covid-19 said it’s too early to make a call on whether the drug works or not, and patients are still being enrolled.

Final results of the trial for the drug, which is manufactured and sold by Fujifilm Holdings Corp., is expected around July, Yohei Doi, a doctor who is leading the trial at Fujita Health University, said in an interview with Bloomberg News.

Doi’s comments came amid conflicting reports over the drug’s efficacy. Japanese media reports on Wednesday said the off-patent drug was not effective based on interim analysis of Doi’s trial, but Prime Minister Shinzo Abe has said he expected the treatment to be approved for use this month.

Doi said that time line seemed tight given how few days remain this month.

Fujifilm Falls

Fujifilm shares fell as much as 4.9% in Tokyo trading Wednesday on the reports, which Doi said were misleading as they’re based on an interim analysis — an independent mid-point review of the results.

“Interim analysis is a routine procedure in these clinical trials,” Doi said, “and it was not meant to evaluate efficacy.”

Doi’s trial, sponsored by Japan’s Ministry of Health, is not connected to two separate randomized control trials Fujifilm is running — one in Japan and one in the U.S. The Japan trial is in progress and is expected to be completed in June, a Fujifilm spokesman said. The U.S. trial is targeted for completion in December.

Also read: US will get Sanofi’s coronavirus vaccine first if the drug giant’s efforts succeed

As the coronavirus continues to spread, upending economies and life around the world, drug companies have been racing to develop treatments and vaccines. Any early and non-conclusive news on these potential medicines has prompted knee-jerk reactions from investors, shifting trillions of dollars in value in the markets.

Shares of vaccine developer Moderna Inc. and drugmaker Gilead Sciences Inc., which manufactures another potential Covid-19 drug remdesivir, have whipsawed in past weeks off similar types of news.

Chief Cabinet Secretary Yoshihide Suga confirmed at a press briefing Wednesday that Japan is targeting an approval for Avigan this month if its safety and efficacy has been proved. Fujifilm said the company has not filed an application to approve Avigan to treat Covid-19 with the Japanese government.

Avigan, also known as favipiravir, has been promoted heavily by the Japanese government despite the lack of conclusive evidence about its efficacy, and has been donated to over 80 countries in recent months. The drug, which has the potential to cause birth defects because of its mechanism of stopping RNA replication, is approved for use in Japan to treat novel influenza.

An early Chinese study of favipiravir, which was not randomized, showed it helped clear the coronavirus in patients earlier than an antiviral HIV medication. The treatment was not added to the recommended Covid-19 regimen in China after an official said in March it was considering the matter.

Likely Inconclusive

As the principal researcher, Doi is prevented from seeing the interim results to maintain objectivity, but said he expects it was likely inconclusive as he is still continuing the enrollment.

The interim analysis is done to check if the drug “is working way better than expected or if there’s unexpected adverse events. That doesn’t seem to be the case either way,” he said. –Bloomberg 

Also read: How India can be a world leader in making Covid vaccine and keeping it cheap too


Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises.

But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle.

ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here.

Support Our Journalism